Nucana Plc Stock Today
| NCNA Stock | USD 1.29 0.04 3.01% |
Performance0 of 100
| Odds Of DistressOver 85
|
NuCana PLC is trading at 1.29 as of the 29th of November 2024, a 3.01 percent decrease since the beginning of the trading day. The stock's open price was 1.33. NuCana PLC has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for NuCana PLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of September 2017 | Category Healthcare | Classification Health Care |
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom. Nucana Plc is traded on NASDAQ Exchange in the United States. The company has 2.25 M outstanding shares of which 63.1 K shares are now shorted by private and institutional investors with about 0.31 trading days to cover. More on NuCana PLC
Moving against NuCana Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
NuCana Stock Highlights
| CEO, Founder, Director | Hugh Griffith | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNuCana PLC can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NuCana PLC's financial leverage. It provides some insight into what part of NuCana PLC's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
NuCana PLC (NCNA) is traded on NASDAQ Exchange in USA. It is located in 3 Lochside Way, Edinburgh, United Kingdom, EH12 9DT and employs 25 people. NuCana PLC is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.9 M. NuCana PLC conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.25 M outstanding shares of which 63.1 K shares are now shorted by private and institutional investors with about 0.31 trading days to cover.
NuCana PLC currently holds about 46.53 M in cash with (26.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9.
Check NuCana PLC Probability Of Bankruptcy
Ownership AllocationAround 87.67 % of NuCana PLC outstanding shares are held by general public with 0.52 percent owned by insiders and only 11.81 (percent) by institutions.
Check NuCana Ownership Details
NuCana Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Castleview Partners, Llc | 2024-09-30 | 0.0 | |
| Traynor Capital Management, Inc | 2024-06-30 | 0.0 | |
| The Carlyle Group Inc | 2024-09-30 | 133.3 K | |
| Baillie Gifford & Co Limited. | 2024-09-30 | 36.7 K | |
| Renaissance Technologies Corp | 2024-09-30 | 16.8 K | |
| Glass Jacobson Investment Advisors Llc | 2024-06-30 | 15 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 3.1 K | |
| Edmond De Rothschild Holding S.a. | 2024-09-30 | 1000 | |
| Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 211 | |
| Allsquare Wealth Management Llc | 2024-09-30 | 205 | |
| Activest Wealth Management | 2024-06-30 | 33.0 |
NuCana PLC Historical Income Statement
NuCana Stock Against Markets
NuCana PLC Corporate Management
| David Harrison | Head Medicine | Profile | |
| Gordon Kennovin | Senior Development | Profile | |
| MD FACOG | Chief Officer | Profile | |
| Stuart Grant | Senior Affairs | Profile | |
| Donald Munoz | Chief Officer | Profile | |
| Theresa Bruce | Senior Operations | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NuCana PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade NuCana Stock refer to our How to Trade NuCana Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NuCana PLC. If investors know NuCana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NuCana PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.77) | Return On Assets (0.68) | Return On Equity (1.81) |
The market value of NuCana PLC is measured differently than its book value, which is the value of NuCana that is recorded on the company's balance sheet. Investors also form their own opinion of NuCana PLC's value that differs from its market value or its book value, called intrinsic value, which is NuCana PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NuCana PLC's market value can be influenced by many factors that don't directly affect NuCana PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NuCana PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if NuCana PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NuCana PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.